Anti-HER2therapyHER-2/neubreastcancerelderlyTargeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been ...
[4]Nakada T,Sugihara K,Jikoh T,et al.The Latest Research and Development into the Antibody-Drug Conjugate,[fam-]Trastuzumab Deruxtecan(DS-8201a),for HER2 Cancer Therapy.Chem Pharm Bull(Tokyo).2019;67(3):173-185. [5]Ogitani Y,Aid...
We also discuss the future development of anti-HER2 therapy in metastatic breast cancer (MBC). 2 Current anti-HER2 therapies by mechanism of action 2.1 Monoclonal antibodies There are three monoclonal antibodies against HER2 that are currently approved: trastuzumab, pertuzumab, and margetuximab. ...
[4] Nakada T, Sugihara K, Jikoh T, et al. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo). 2019;67(3):173-185. [...
the key finding is that the relative benefit of these therapies may depend on the level of HER2 amplification. Patients with higher levels of HER2 amplification appeared to benefit more from anti-HER2 therapy and less from anti-EGFR therapy, and vice-versa. This can aid refining patient selectio...
Abstract 3803: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer doi:10.1158/1538-7445.AM2019-3803Amplification of chromosome 17q23 is a frequent genomic event that occurs in ~ 11% of human breast cancers. The 17q23 amplification is enriched in ...
Targeting anti-HER-2 therapy, trastuzumab, Lapatinib, T-DM1, and Pertuzumab is a standard therapy for HER-2-overexpressing breast cancer. But there are less data available related to anti-HER-2 therapy in elderly patients because they have been consistently underrepresented in clinicaltrials. Anti...
Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy. Results Disease-free survival (DFS) was 75% after 5 and 61% after 10 years, respectively. Patients with HER...
Current methods to determine HER2 (human epidermal growth factor receptor 2) status are affected by reproducibility issues and do not reliably predict benefit from anti-HER2 therapy. Quantitative measurement of HER2 may more accurately identify breast cancer (BC) patients who will respond to anti-HER2...
breast cancer results in aberrant elevation of WIP1 and miR-21, which not only contributes to breast tumorigenesis, but also causes resistance to anti-HER2 therapy. Therefore, targeted inhibition of WIP1 and miR-21 could be an effective therapeutic approach for trastuzumab-resistant HER2+ breast ...